You are viewing an incomplete version of our website. Please click to reload the website as full version.

anti-B-Cell CLL/lymphoma 9-Like (BCL9L) Antibodies

BCL9 is associated with B-cell acute lymphoblastic leukemia. Additionally we are shipping B-Cell CLL/lymphoma 9-Like Kits (6) and B-Cell CLL/lymphoma 9-Like Proteins (3) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
BCL9L 77578 Q9D219
BCL9L 607 O00512
BCL9L 300673  
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-B-Cell CLL/lymphoma 9-Like Antibodies at antibodies-online.com

Showing 10 out of 30 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Human Rabbit Un-conjugated EIA, WB Western blot analysis of Bcl9L in HeLa cell lysate with Bcl9L antibody at 1 μg/ml in (A) the absence and (B) the presence of blocking peptide. 0.1 mg Log in to see 6 to 8 Days
$401.50
Details
Human Rabbit Un-conjugated WB BCL9L Antibody (N-term) (ABIN1881110) western blot analysis in human placenta tissue lysates (35 µg/lane). This demonstrates the BCL9L antibody detected the BCL9L protein (arrow). 400 μL Log in to see 10 to 11 Days
$324.50
Details
Human Rabbit Un-conjugated WB 400 μL Log in to see 6 Days
$457.14
Details
Human Rabbit PE ELISA, WB   200 μL Log in to see 8 to 10 Days
$969.83
Details
Human Rabbit Un-conjugated ELISA, WB 0.1 mg Log in to see 6 to 11 Days
$535.71
Details
Human Rabbit Un-conjugated ELISA, WB Western blot analysis of Bcl9L in HeLa cell lysate with Bcl9L antibody at 1 µg/mL in (A) the absence and (B) the presence of blocking peptide. 0.1 mg Log in to see 2 to 3 Days
$330.00
Details
Human Rabbit Un-conjugated ELISA   200 μL Log in to see 8 to 10 Days
$713.17
Details
Human Rabbit Un-conjugated ELISA, WB   200 μL Log in to see 11 to 16 Days
$532.71
Details
Human Rabbit APC ELISA, WB   200 μL Log in to see 16 Days
$710.29
Details
Human Rabbit FITC ELISA, WB   200 μL Log in to see 16 Days
$710.29
Details

BCL9L Antibodies by Reactivity, Application, Clonality and Conjugate

Attributes Applications Host Clonality Conjugate
Mouse (Murine)


Human ,
,
,
, , , , ,
Rat (Rattus)


Top referenced anti-B-Cell CLL/lymphoma 9-Like Antibodies

  1. Human Polyclonal BCL9L Primary Antibody for WB - ABIN1881110 : Miller, Rutherford, Johnson, Fiedler, Bienz: Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor. in Journal of molecular biology 2010 (PubMed)
    Show all 5 references for ABIN1881110

  2. Human Polyclonal BCL9L Primary Antibody for EIA, WB - ABIN783409 : Adachi, Jigami, Yasui, Nakano, Ohwada, Omori, Sugano, Ohkawara, Shibuya, Nakamura, Akiyama: Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. in Cancer research 2004 (PubMed)
    Show all 4 references for ABIN783409

More Antibodies against B-Cell CLL/lymphoma 9-Like Interaction Partners

Mouse (Murine) B-Cell CLL/lymphoma 9-Like (BCL9L) interaction partners

  1. Study demonstrates that the Golgi resident protein GM130 (show GOLGA2 Antibodies) activates the spindle assembly factor TPX2 (show DAZL Antibodies) to nucleate microtubules around the Golgi and further captures them to couple mitotic membranes to the spindle.

  2. BCL9-2 induces ER positive breast cancers in vivo, regulates ER expression by a novel ss-catenin independent mechanism in breast cancer cells.

  3. Pax6 (show PAX6 Antibodies), the master regulator of eye development, directly activates Bcl9 (show BCL9 Antibodies)/9l transcription.

  4. Data show that the GCM1/syn (show CTNNB1 Antibodies)cytin (show BCL9 Antibodies)-B pathway is significantly downregulated in the placenta of BCL9L-defici (show GCM1 Antibodies)ent mice (show ERVW-1 Antibodies)and that the fusion and differentiation of ST-II cells are blocked.

  5. BCL9-2 promotes early phases of intestinal tumor progression in humans and in transgenic mice. BCL9-2 increases the expression of a subset of canonical Wnt (show WNT2 Antibodies) target genes but also regulates genes that are required for early stages of tumor progression.

  6. These results suggest a critical role of BCL9 (show BCL9 Antibodies)/9-2 in the Wnt (show WNT2 Antibodies)-mediated regulation of adult, as opposed to embryonic, myogenic progenitors.

  7. We demonstrated that nuclear B9L expression was closely associated with the high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 (show ERBB2 Antibodies) in breast cancers.

Human B-Cell CLL/lymphoma 9-Like (BCL9L) interaction partners

  1. BCL9 (show BCL9 Antibodies)/9L-beta-catenin (show CTNNB1 Antibodies) Signaling is Associated With Poor Outcome in Colorectal Cancer

  2. BCL9 (show BCL9 Antibodies) is a molecular driver of DCIS invasive progression.

  3. PCDH10 (show PCDH10 Antibodies) antagonized MM cell proliferation via the downregulation of Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies)/BCL-9 (show BCL9 Antibodies) signaling, whereas PCDH10 (show PCDH10 Antibodies) repressed the expression of AKT (show AKT1 Antibodies) to promote the expression of GSK3beta (show GSK3b Antibodies) and then to restrain the activation of beta-catenin (show CTNNB1 Antibodies)

  4. The inhibition of the transcriptional activity of BCL9-2 by WWOX (show WWOX Antibodies) and HDAC3 (show HDAC3 Antibodies) constitutes a new molecular mechanism and provides new insight for a broad range of cancers.

  5. BCL9-2 induces ER positive breast cancers in vivo, regulates ER expression by a novel ss-catenin independent mechanism in breast cancer cells.

  6. By beta-catenin's association with LEF1 (show LEF1 Antibodies) and BCL9-2/B9L.

  7. MiR (show MLXIP Antibodies)-30-5p downregulation occurs as a result of interaction between multiple myeloma cells and bone marrow stromal cells, which in turn enhances expression of BCL9 (show BCL9 Antibodies).

  8. we detected five SNPs in the first two genes/loci - BCL9 and C9orf5 - strongly associated with negative symptoms of schizophrenia

  9. Inhibition of the BCL9 (show BCL9 Antibodies)-beta-catenin (show CTNNB1 Antibodies) interaction and selectively suppresses oncogenic Wnt (show WNT2 Antibodies) transcription.

  10. growth factor induced proliferation mediates a neutralizing response by significantly increasing miR (show MLXIP Antibodies)-30c-2* which reduces BCL9 (show BCL9 Antibodies) expression and cell proliferation in SKOV-3 and OVCAR-3 cells

B-Cell CLL/lymphoma 9-Like (BCL9L) Antigen Profile

Protein Summary

BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.

Gene names and symbols associated with BCL9L

  • B-cell CLL/lymphoma 9-like (BCL9L) antibody
  • B cell CLL/lymphoma 9 (Bcl9) antibody
  • B cell CLL/lymphoma 9-like (Bcl9l) antibody
  • B-cell CLL/lymphoma 9 (BCL9) antibody
  • B-cell CLL/lymphoma 9-like (Bcl9l) antibody
  • B-cell CLL/lymphoma 9-like (bcl9l) antibody
  • 2610202E01Rik antibody
  • 8030475K17Rik antibody
  • A330041G23Rik antibody
  • B9L antibody
  • BC003321 antibody
  • bcl9-2 antibody
  • BCL9L antibody
  • DLNB11 antibody
  • Gm130 antibody
  • LGS antibody

Protein level used designations for BCL9L

B-cell CLL/lymphoma 9-like , b-cell CLL/lymphoma 9-like protein-like , B-cell CLL/lymphoma 9 protein , B-cell lymphoma 9 protein , bcl-9 , nuclear co-factor of beta-catenin signalling , B-cell CLL/lymphoma 9-like protein , B-cell lymphoma 9-like protein , BCL9-like protein , BCL9-related beta-catenin-binding protein , protein BCL9-2 , protein legless homolog

GENE ID SPECIES
419785 Gallus gallus
451596 Pan troglodytes
489377 Canis lupus familiaris
539340 Bos taurus
100063146 Equus caballus
100444640 Pongo abelii
100515846 Sus scrofa
77578 Mus musculus
80288 Mus musculus
607 Homo sapiens
100155378 Sus scrofa
283149 Homo sapiens
300673 Rattus norvegicus
449532 Danio rerio
Selected quality suppliers for anti-B-Cell CLL/lymphoma 9-Like (BCL9L) Antibodies
Did you look for something else?